No Data
Is Zai Lab (NASDAQ:ZLAB) Using Too Much Debt?
Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...
Express News | The third day of the medical insurance negotiation "opened", with enterprises such as Zaidong, Dize, and Shenwei entering the scene.
Cantor Fitzgerald Reiterates Overweight on Zai Lab
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)